Literature DB >> 23021037

Role of genomics on the path to personalized medicine.

Johanne Tremblay1, Pavel Hamet.   

Abstract

Technology continues to lead the field of personalized medicine as the interpretation of the human genome is progressing. The cost and duration of genomic sequencing continue to decrease sharply and there is intensive research aimed at understanding how the changes that occur within the genome can alter its function and the genomic variations that constitute individual susceptibility to diseases and responses to therapy. The overlay of a personal genome with the personal medical record of patients has a potential to improve prediction and prevention and to allow a more pro-active therapeutic strategy. It is evident that pharmacogenomics and individualized drug therapy are the building blocks of personalized medicine. A growing number of drugs are now used for the treatment of cancer in subjects selected by a companion genetic test. Personalized medicine while based upon genomic knowledge of the individual requires equally essential personalised environmental information as well as the understanding of every subject's capacity for health-promoting behaviour.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021037     DOI: 10.1016/j.metabol.2012.08.023

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  13 in total

1.  Risks of nutrigenomics and nutrigenetics? What the scientists say.

Authors:  T Hurlimann; V Menuz; J Graham; J Robitaille; M-C Vohl; B Godard
Journal:  Genes Nutr       Date:  2013-11-29       Impact factor: 5.523

2.  Hot melt extrusion paired fused deposition modeling 3D printing to develop hydroxypropyl cellulose based floating tablets of cinnarizine.

Authors:  Anh Q Vo; Jiaxiang Zhang; Dinesh Nyavanandi; Suresh Bandari; Michael A Repka
Journal:  Carbohydr Polym       Date:  2020-06-04       Impact factor: 9.381

3.  Physician Knowledge of Human Genetic Variation, Beliefs About Race and Genetics, and Use of Race in Clinical Decision-making.

Authors:  Sherrill L Sellers; Brooke A Cunningham; Vence L Bonham
Journal:  J Racial Ethn Health Disparities       Date:  2018-06-20

4.  Valvejet Technology for the Production of a Personalised Fixed Dose Combination of Ramipril and Glimepiride: an Investigative Study on the Stability of Ramipril.

Authors:  Gayathri Kollamaram; Alexandra Faucher; Denise M Croker; Gavin M Walker
Journal:  Pharm Res       Date:  2018-07-27       Impact factor: 4.200

Review 5.  Targeting epigenetics using synthetic lethality in precision medicine.

Authors:  Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2018-07-12       Impact factor: 9.261

Review 6.  An overview of recommendations and translational milestones for genomic tests in cancer.

Authors:  Christine Q Chang; Sharna R Tingle; Kelly K Filipski; Muin J Khoury; Tram Kim Lam; Sheri D Schully; John P A Ioannidis
Journal:  Genet Med       Date:  2014-10-23       Impact factor: 8.822

Review 7.  Pre-graduate and post-graduate education in personalized medicine in the Czech Republic: statistics, analysis and recommendations.

Authors:  Jiri Polivka; Jiri Polivka; Marie Karlikova; Ondrej Topolcan
Journal:  EPMA J       Date:  2014-12-15       Impact factor: 6.543

8.  Mutations Causing Complex Disease May under Certain Circumstances Be Protective in an Epidemiological Sense.

Authors:  Sabine Siegert; Andreas Wolf; David N Cooper; Michael Krawczak; Michael Nothnagel
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

9.  African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.

Authors:  Ripudaman K Bains
Journal:  Evol Med Public Health       Date:  2013-05-15

10.  Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?

Authors:  Naomi E van der Sligte; Kim R Kampen; Eveline S J M de Bont
Journal:  Cell Mol Life Sci       Date:  2015-08-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.